文献速递免疫规划卫生政策与健康促进

台湾地区HPV疫苗接种的不良事件

Adverse events from HPV vaccination in Taiwan.
PubMed 文献 · Vaccine · 2023-11-10

本研究利用台湾地区2013至2018年12至15岁初中女生HPV疫苗接种记录与国家健康保险数据库串联,以19种严重疾病为严重不良事件,比较接种组与同龄人群发病率并计算标准化发病比(SIR)。结果显示19种严重不良事件风险均无统计学显著升高,未发现HPV疫苗接种与严重不良事件存在关联。

要点

  • 研究期间发病率最高的严重不良事件为纤维肌痛(73.23例/百万人口),最低为克罗恩病(0.15例/百万人口)。
  • 19种选定的严重不良事件风险均无统计学显著升高,未发现HPV疫苗接种与严重不良事件存在关联。
  • 作者认为鉴于HPV疫苗的获益与安全性,本研究可减少对疫苗副作用的担忧,为卫生政策提供信息并提高公众和临床医生对HPV疫苗政策的接受度。

核心结论

  • 19种选定的严重不良事件风险均无统计学显著升高,未发现HPV疫苗接种与严重不良事件存在关联。
  • 作者认为鉴于HPV疫苗的获益与安全性,本研究可减少对疫苗副作用的担忧,为卫生政策提供信息并提高公众和临床医生对HPV疫苗政策的接受度。

研究设计与样本

  • 回顾性队列研究,使用台湾地区国家免疫信息系统中2013至2018年12至15岁初中女生HPV疫苗接种记录,串联国家健康保险数据库被保险人登记数据建立接种组。
  • 以19种严重疾病为严重不良事件,比较接种组与同龄人群的发病率并计算标准化发病比(SIR)。
  • 设定接种后三个观察期:3个月内、1年内及研究期间(2013-2018年)。

主要发现

  • 研究期间发病率最高的严重不良事件为纤维肌痛(73.23例/百万人口)。
  • 研究期间发病率最低的严重不良事件为克罗恩病(0.15例/百万人口)。
  • 19种选定的严重不良事件风险均无统计学显著升高。

关键数值与推荐

  • 研究期间纤维肌痛发病率为73.23例/百万人口。
  • 研究期间克罗恩病发病率为0.15例/百万人口。

临床怎么用

  • 作者认为鉴于HPV疫苗的获益与安全性,本研究可减少对疫苗副作用的担忧,为卫生政策提供信息并提高公众和临床医生对HPV疫苗政策的接受度。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The safety of human papillomavirus (HPV) vaccines has been evaluated continuously in pre-licensure clinical trials, post-marketing surveillance systems, and observational studies. Most studies have found no significant association between serious adverse events and HPV vaccination. However, these studies have focused on Western populations; similar studies focusing on Asian populations are insufficient. Our retrospective cohort study used the HPV-vaccination records of junior high-school adolescent girls aged 12-15 years between 2013 and 2018 in Taiwan's National Immunization Information System and linked them to a registry for beneficiaries in Taiwan's National Health Insurance Database (NHID) to establish the vaccinated group. We selected 19 serious diseases as serious adverse events. We compared the incidence rates of these serious adverse events between the vaccinated group and girls in the same age group population, and we calculated the standardized incidence ratio (SIR) to evaluate the risk of serious adverse events after HPV vaccination. Because of the onset of different types of diseases, we set three periods after the subjects received HPV vaccination: within 3 months, within 1 year, and during the study period (2013-2018). The results showed the incidence rates and the SIRs of 19 selected adverse events. Among the 19 selected serious adverse events, the disease with the highest incidence rate during the study period was fibromyalgia (73.23 cases per million population), and the disease with the lowest incidence rate during the study period was Crohn's disease (0.15 cases per million population). The results showed no statistically significant increases in the risk of 19 selected serious adverse events and indicated no association between HPV vaccination and serious adverse events. Given the benefits and safety of HPV vaccination, our research can reduce concerns about vaccine side effects, inform health policies and improve public and clinician's acceptance of HPV vaccine policy.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Tsai SA, Lu CY, Chen TI, et al. Adverse events from HPV vaccination in Taiwan. Vaccine. 2023. PMID: 37949754. doi:10.1016/j.vaccine.2023.11.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。